Healthcare Triangle, Inc. reports developments in healthcare information technology, digital health platforms, cloud enablement, managed services, and data analytics for healthcare and life sciences organizations. Company news includes product and customer updates involving hospital information management, interoperability, telehealth, AI-powered clinical and operational automation, and customer-engagement tools.
Recurring HCTI updates also cover subsidiary activity at QuantumNexis, international expansion across Africa, the Middle East, and related healthcare markets, partnership and joint-venture activity, and capital-structure actions such as share repurchase authorization and reverse stock split disclosures.
Healthcare Triangle (HCTI) announced that its wholly owned subsidiary Purpose Health signed multi-year agreements for healthcare technology services. A master services agreement with a university health system covers electronic health record (EHR) optimization and healthcare cybersecurity. A separate multi-year agreement provides IT services supporting a healthcare business unit's Global Capability Center.
The agreements follow Purpose Health's July 2026 launch. The subsidiary also advises hospitals and health systems in Idaho, Vermont and New York on Rural Health Transformation projects using MEDITECH. The federal program provides $50 billion to states over five years; that amount is program funding, not an award to HCTI. Purpose Health is also developing AI solutions for pharmaceutical clients.
Healthcare Triangle (Nasdaq: HCTI) will implement a 1-for-20 reverse stock split, effective October 26, 2026, at 12:01 a.m. Eastern Time. Post-split trading on the Nasdaq Capital Market is scheduled to begin at the market opening that day, pending confirmation by the Depository Trust Company and Nasdaq.
The company expects the split to increase its share price as part of its strategy to regain compliance with Nasdaq's $1.00 minimum bid price requirement. Each twenty outstanding shares will convert into one share, reducing outstanding common stock from approximately 17,730,008 shares to approximately 886,501 shares. The total number of authorized shares will remain unchanged.
Healthcare Triangle (HCTI) announced six signed client engagements at its Teyame business, with services scheduled to begin in October and November 2026. Management estimates the engagements will generate approximately $1.34 million in annual revenue at full run rate.
Teyame expects to sign a separate engagement targeting approximately $3.31 million in incremental annual revenue beginning in January 2027. That engagement remains unsigned. If it is signed and all seven engagements reach their targeted annual run rates, the combined amount would be approximately $4.65 million. These figures are not revenue forecasts for any fiscal period.
Healthcare Triangle (Nasdaq: HCTI) signed a memorandum of understanding with AI World to establish a proposed North American humanoid nursing robot venture.
HCTI expects to own 70% of the venture, with AI World owning 30%. The proposed company would hold North American intellectual property and distribution rights for robots intended to assist with patient toileting and hygiene under clinical supervision. HCTI plans to use its network of over 140 hospital relationships to bring the robots to market after required approvals and regulatory clearances.
The MOU is non-binding except for certain provisions, including exclusivity and confidentiality. Formation requires due diligence, definitive agreements, board and other required approvals, and regulatory clearances. Clinical validation and hospital pilots are planned before commercialization. The parties expect to negotiate definitive agreements over the coming months.
Healthcare Triangle (HCTI) signed a non-binding Letter of Intent on September 23, 2026 to acquire Roboticom’s industrial precision robotics automation business from Crestpoint Capital for total consideration of up to $30 million in cash and equity paid over time.
The proposed deal covers 100% of Roboticom customer contracts, specified intellectual property, trademarks and related business assets. Roboticom, based in Pisa, Italy, sells SandRob™, ORTIS™ and ScultoRob™ systems for precision surface treatment across aerospace, marine, composites, orthotics and prosthetics, automotive, advanced manufacturing and industrial tooling sectors.
Based on unaudited data from current owners, Roboticom generated about $14.1 million in revenue, $6.9 million in gross margin and was EBITDA-positive in fiscal 2025. Roboticom management’s unaudited plan targets approximately $153.5 million in revenue and $64 million in adjusted operating contribution by fiscal 2029/30, but these projections are unverified by HCTI, not endorsed by HCTI and subject to significant uncertainty.
Healthcare Triangle (HCTI) has joined the newly launched Kanzun-ARCB Growth Fund as the U.S. technology and capital-markets partner, aiming to help Malaysian healthcare companies prepare for entry into U.S. markets.
The fund is based on a Memorandum of Understanding signed in Kuala Lumpur between ARCB Investment and Kanzun Ventures Management. ARCB contributes roughly AED 300 million in assets under management and a network of investors across the Middle East and Asia, while Kanzun leads deal sourcing and portfolio development in Malaysia. HCTI will apply its Nasdaq-listed experience and expertise in AI, cloud, data and digital infrastructure to prepare qualifying Malaysian healthcare companies technologically and financially for potential U.S. capital-market expansion, creating a corridor from Malaysia through Middle Eastern capital to the United States.
Healthcare Triangle (HCTI) approved a stock dividend of a minority interest in Teyame AI Holdings common shares for existing HCTI shareholders, tied to a planned direct listing of Teyame AI Holdings on NASDAQ.
HCTI signed a Separation Agreement with its subsidiary Teyame AI Holdings that governs the separation, including allocation of assets and liabilities and transition services. Teyame AI Holdings owns HCTI’s recently acquired AI-powered customer experience businesses, Teyame 360 S.L. and Datono Mediación S.L. Completion of the direct listing depends on SEC review of a Teyame AI Holdings registration statement and NASDAQ approval of the listing. The stock dividend will be distributed to HCTI common shareholders of record on a future record date, which will be set after NASDAQ approves the direct listing.
Healthcare Triangle (Nasdaq: HCTI) reported Q2 2026 revenue of $9.19 million, a 158% year-over-year increase, with gross profit rising 322% to $2.07 million. Gross margin expanded to 22.5% from 13.8%, driven largely by its AI-powered customer engagement platform.
The AI platform contributed $6.31 million in Q2 revenue, about 69% of the total, and generated $1.64 million in segment gross profit at roughly 26% margin. For the first half of 2026, revenue reached $19.05 million and gross profit $4.46 million, up 162% and 444% year over year, respectively, with gross margin at 23.4%. Stockholders' equity increased to $49.1 million as of June 30, 2026, from $9.9 million at year-end 2025, reflecting a stronger balance sheet.
Healthcare Triangle (Nasdaq: HCTI) reported that subsidiary Teyame has, by June 2026, generated from a major Spanish health insurance client the same level of revenue it recorded from that client during all of 2025. The company projects this client could deliver €2 million in annual revenue for Teyame.
Teyame manages the client's omnichannel customer acquisition through AI-driven engagement and direct account management. According to Healthcare Triangle, these results highlight growth across its subsidiaries and support the strategic rationale for acquiring Teyame 360 SL and Datono Mediacion SL, the Spain-based entities behind Teyame's AI-powered customer experience platform.
Healthcare Triangle (Nasdaq: HCTI) signed a non-binding LOI to acquire a 51% equity stake in Melbourne-based CosmoAesthetics (CosmoInnovations) for a proposed US $23.5 million, payable in cash, equity and performance-linked milestones over three years.
According to Healthcare Triangle, the deal would shift its model from healthcare IT services toward a product-led innovation platform combining its AI and digital infrastructure with CosmoInnovations' MedTech, BeautyTech and consumer-health portfolio. CosmoInnovations contributes more than 25 proprietary technologies, 27 granted patents and 61 pending patent applications across skincare, light therapy, respiratory wellness, oral health, pain management, transdermal delivery and home-based care. CosmoInnovations’ management targets over US $50 million in cumulative revenue in the first three years post-acquisition, with an estimated US $33 million annualized run-rate by Year 3, though there is no assurance these targets will be achieved. Healthcare Triangle plans immediate independent IP and financial due diligence, and notes FDA establishment registration for a key LED technology manufacturer does not equal FDA clearance or approval.